10x Genomics Inc Class A (TXG)

10x Genomics's stock price has experienced fluctuations over the past six months. On May 5, 2026, the stock price was $22.01 per share, a 171.73% increase from $8.10 per share on May 6, 2025. The 52-week trading range has been between $8.06 and $26.45. Recent events include a stock drop after Q1 2026 results due to concerns about future growth, despite beating estimates; the Q1 2026 revenue report showing a decrease year-over-year but an increase excluding a one-time settlement; gains ahead of the Q1 2026 earnings report; a rise in stock price following the launch of the Atera platform; and a surge driven by investor enthusiasm for the company's role in spatial biology initiatives. The company released its Fourth Quarter and Full Year 2025 earnings on February 12, 2026, and its Third Quarter 2025 earnings on November 6, 2025. The stock is considered highly volatile.

Demand for 10x Genomics's products and services exhibits certain patterns. The company has seen double-digit growth in consumables revenue, particularly in single-cell and spatial consumables. New products with more accessible pricing are also unlocking new waves of single-cell demand. However, the company has experienced a cyclical slowdown in instrument demand, partly due to the normalization of sales post-COVID. Management has projected sequential revenue declines in Q2 and Q3 2026, attributing this to Atera-related purchasing delays, with a limited ramp-up of Atera expected in Q4 2026. Analysts anticipate a modest revenue decline of 2.9% over the next 12 months.

10x Genomics, Inc. is a life science technology company that develops and sells integrated solutions for analyzing biological systems. Its product offerings include the Chromium platform for single-cell analysis and the Visium and Xenium platforms for spatial genomics. In April 2026, 10x Genomics introduced Atera, a new in situ spatial biology platform engineered for whole-transcriptome spatial analysis with single-cell sensitivity at an unprecedented scale, with shipments expected in the second half of 2026.

10x Genomics serves a global customer base, including academic institutions, pharmaceutical and biotechnology companies, and government research organizations. The company's operations span the United States, the rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. It has established regional operations and support centers across North America, Europe, and Asia, with specific locations in Asia including Jui Bei City, Taiwan; Shanghai, China; Singapore; and Tokyo, Japan.

In the past year, 10x Genomics has built its reputation on enabling new discoveries in fields such as oncology, immunology, neuroscience, and developmental biology. The company has engaged in significant partnerships, including with the Chan Zuckerberg Initiative, the Arc Institute, and Xaira Therapeutics. In April 2026, 10x Genomics announced a partnership with Bioptimus to launch STELA, a global initiative aimed at profiling patient tissue specimens to build a data backbone. The launch of the Atera platform has been highlighted as the most significant product introduction in the company's history.

Ownership of 10x Genomics, Inc. is predominantly held by institutional investors, with estimates ranging from approximately 96.93% to 99.74% as of July 2025. Major institutional shareholders include Vanguard Group Inc., ARK Investment Management LLC, Fmr Llc, and BlackRock, Inc. Cathie Wood is noted as owning the most shares of 10x Genomics Inc.